Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Conditions

Tuberous Sclerosis 6Seizures 5Marijuana Abuse 3Lennox Gastaut Syndrome 3Epilepsies, Myoclonic 3Colonic Neoplasms 3Breast Neoplasms 3Sturge-Weber Syndrome 2Neoplasms 2Nausea 2Glioblastoma 2Anxiety Disorders 2Vomiting 1Tuberous Sclerosis 2 1Tuberous Sclerosis 1 1Spasms, Infantile 1Solid Tumor 1Rectal Neoplasms 1Prostatic Neoplasms 1Parasomnias 1Pancreatic Neoplasms 1Pain 1Multiple Myeloma 1Liver Neoplasms 1Liver Cirrhosis 1Gallbladder Neoplasms 1Epilepsy 1Dysgeusia 1Drug Resistant Epilepsy 1Colorectal Neoplasms 1

Interventions

Cannabidiol 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Spasms, Infantile × Cannabidiol × Clear all
NCT04485104 2025-10-31

Assessment of Adjunctive Cannabidiol Oral Solution (GWP42003-P) in Children With Tuberous Sclerosis Complex (TSC), Dravet Syndrome (DS), or Lennox-Gastaut Syndrome (LGS) Who Experience Inadequately-controlled Seizures

Jazz Pharmaceuticals

Phase 3 Terminated
3 enrolled 28 charts

Tuberous Sclerosis 1, Tuberous Sclerosis 2, Epilepsy, Epilepsies, Myoclonic, Seizures, Spasms, Infantile, Tuberous Sclerosis, Lennox Gastaut Syndrome

Data powered by HemOnc (CC BY 4.0) Colophon âš¡